Is Hims & Hers Stock a Buy Right Now in September? | HIMS Stock Analysis

Parkev Tatevosian, CFA•Sep 16, 2026

Summary

Parkev highlights that Hims & Hers management is forecasting at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. Parkev states that the company has shown explosive growth, increasing revenue from approximately $250 million in 2020 to a trailing 12-month total of $2.6 billion. Parkev notes that the acquisition of Eucalyptus has facilitated robust international expansion and the company has recently surpassed the milestone of 3 million members. Parkev explains that the healthcare industry is ripe for disruption due to widespread consumer dissatisfaction, providing a significant tailwind for Hims & Hers.

Parkev cautions that despite the growth, the company's financial metrics remain volatile. Parkev observes that operating profit margins and returns on invested capital have fluctuated significantly as the company invests in marketing and prepares for FDA approval of new peptides. Parkev calculates a fair value for the stock at $27.50, which is close to the current market price of $28.80. Parkev concludes that while the stock is fairly valued, it is a suitable buying opportunity only for investors who can handle a high-beta, high-risk profile.

Hims & Hers (HIMS): Parkev argues that the company is successfully capturing market share from traditional healthcare providers by offering a better customer experience. Parkev points out that the stock's beta of 2.4 indicates much higher volatility than the broader healthcare sector. Parkev suggests a fair value of $27.50 and ranks the stock as a buy for long-term, risk-tolerant investors.

Eli Lilly (LLY): Parkev mentions Eli Lilly as a representative of the traditional, lower-risk pharmaceutical sector for comparison purposes. Parkev notes that established companies like Eli Lilly typically have a beta of less than one, providing a much more stable investment profile. Parkev emphasizes that investors should not mistake the risk profile of Hims & Hers for that of established giants like Eli Lilly.

Novo Nordisk (NVO): Parkev identifies Novo Nordisk as another example of a low-risk business within the pharmaceutical category. Parkev explains that this company offers a stable alternative to the high-volatility nature of Hims & Hers. Parkev uses this comparison to highlight that Hims & Hers operates with a significantly different risk-reward dynamic than industry stalwarts.

Mentioned Stocks

LLY

Sentiment: HOLD

Reasoning: Parkev uses Eli Lilly as a benchmark for a lower-risk healthcare investment. Parkev points out that Eli Lilly has a much lower beta than Hims & Hers, typically less than one, signifying stability. Parkev mentions this stock to warn investors that Hims & Hers does not share the same low-risk characteristics as traditional pharmaceutical giants.

Loading chart...

NVO

Sentiment: HOLD

Reasoning: Parkev mentions Novo Nordisk as an example of a stable, low-risk business in the healthcare sector. Parkev highlights that its volatility is significantly lower than that of Hims & Hers. Parkev utilizes this comparison to illustrate the specific risk profile an investor takes on when choosing a growth-oriented disruptor over an established player.

Loading chart...

HIMS

Sentiment: BUYAction: RECOMMENDED

Reasoning: Parkev identifies Hims & Hers as a high-growth opportunity with a management target of $6.5 billion in revenue by 2030. Parkev notes that the stock is currently fairly valued with a calculated fair value of $27.50 per share compared to its market price near $28.80. Parkev emphasizes that while the stock is risky with a high beta of 2.4, it is an attractive long-term investment for those with high risk tolerance due to its potential to disrupt the healthcare market.

Loading chart...